ATE324118T1 - Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln - Google Patents

Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln

Info

Publication number
ATE324118T1
ATE324118T1 AT01964077T AT01964077T ATE324118T1 AT E324118 T1 ATE324118 T1 AT E324118T1 AT 01964077 T AT01964077 T AT 01964077T AT 01964077 T AT01964077 T AT 01964077T AT E324118 T1 ATE324118 T1 AT E324118T1
Authority
AT
Austria
Prior art keywords
group
treatment
tumors
disubstituted
acetylene
Prior art date
Application number
AT01964077T
Other languages
English (en)
Inventor
Alissar Nehme
Richard L Beard
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE324118T1 publication Critical patent/ATE324118T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01964077T 2000-08-17 2001-08-15 Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln ATE324118T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/640,852 US6903121B1 (en) 2000-08-17 2000-08-17 Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents

Publications (1)

Publication Number Publication Date
ATE324118T1 true ATE324118T1 (de) 2006-05-15

Family

ID=24569947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964077T ATE324118T1 (de) 2000-08-17 2001-08-15 Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln

Country Status (9)

Country Link
US (1) US6903121B1 (de)
EP (1) EP1313509B1 (de)
JP (1) JP2004506011A (de)
AT (1) ATE324118T1 (de)
AU (2) AU8497201A (de)
CA (1) CA2418988A1 (de)
DE (1) DE60119130T2 (de)
ES (1) ES2260278T3 (de)
WO (1) WO2002013808A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4664597B2 (ja) 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US4810804A (en) 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
EP0969847A1 (de) 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene und carticosteroid enthaltende zusammensetzungen zur behandlung von psoriasis
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6114348A (en) 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene
TWI281911B (en) 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
JP2004508334A (ja) 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
EP1351678A2 (de) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Behandlung von neoplastischen erkrankungen mit incensol und/oder furanogermacren

Also Published As

Publication number Publication date
DE60119130T2 (de) 2006-11-30
US6903121B1 (en) 2005-06-07
EP1313509A2 (de) 2003-05-28
ES2260278T3 (es) 2006-11-01
CA2418988A1 (en) 2002-02-21
DE60119130D1 (de) 2006-06-01
AU2001284972B2 (en) 2005-08-25
WO2002013808A3 (en) 2003-04-03
JP2004506011A (ja) 2004-02-26
EP1313509B1 (de) 2006-04-26
AU8497201A (en) 2002-02-25
HK1053980A1 (en) 2003-11-14
WO2002013808A2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
HRP20030831B1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
GEP20053692B (en) Substituted Alkylamine Derivatives and Methods of Use
CY1114535T1 (el) Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
NZ515669A (en) Beta 2 adrenoceptor agonists
PT1068870E (pt) Agentes antitumorais
AR027355A1 (es) Acidos tiazolidincarboxilicos
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
ATE331703T1 (de) Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
DK1056704T3 (da) Antitumormidler
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
IL159993A0 (en) Platinum complexes and their use in cancer treatment
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
IL165086A0 (en) Cyanoguanidine prodrugs
GEP20043239B (en) C10 Carbonate Substituted Taxanes as Antitumor Agents
DE60119130D1 (de) Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
BR0104353A (pt) Taxanos heterosubstituìdos com acetato c7 como agentes antitumor
AU2001282238A1 (en) Dihydroporphyrin derivatives and their uses
GEP20043323B (en) C10 Carbonate Substituted Taxanes as Antitumor Agents
NO20012169L (no) Forbindelser med veksthormonfrigjörende egenskaper

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties